Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown efficacy in immunocompromised adults, the pharma announced Monday. In substudy B of Pfizer’s ongoing Phase 3 MONeT trial, Abrysvo ...
Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...
Pfizer Inc ($PFE) announced an update on their ongoing clinical study. Pfizer has completed a Phase 1 trial titled “A Phase 1, Randomized, ...
Tuesday Pfizer announced it's expanding its clinical trials for younger children ages 5 to 11-years-old. Medical doctors are calling this the final frontier. This is a 2-year study, where a subset of ...
Pfizer is mulling its options after its investigational sickle cell disease drug failed to meet the primary endpoint in a Phase III trial. The THRIVE-131 study (NCT04935879) was evaluating inclacumab, ...
Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.
At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback